Home › Companies › Protara Therapeutics, Inc. › 2025-2026

Protara Therapeutics, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Protara Therapeutics, Inc.’s Form 8-K, filed 2026-06-15 (Item 5.07 on EDGAR). Page generated 04 October 2026.

9Reported items
112Asset managers
1,110Fund votes
2026-06-12Meeting date

Proxy season: 2025-2026

Explore Protara Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Protara Therapeutics, Inc.

These tallies are Protara Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-15 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Protara Therapeutics, Inc. — official shareholder meeting results, meeting held 2026-06-12
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Jesse Shefferman	26,672,259	--	--	4,241,606	14,185,811	Majority: yes
Elect Director: Barry Flannelly, Pharm.D.	25,409,066	--	--	5,504,799	14,185,811	Majority: yes
Elect Director: Cynthia Smith	22,371,125	--	--	8,542,740	14,185,811	Majority: yes
Proposal 2. Ratification of the Selection of Independent Registered Public Accounting Firm.	45,012,036	74,615	13,025	--	--	Majority: yes
Proposal 3. Approval, on an Advisory Basis, of the Compensation of the Company's Named Executive Officers.	29,208,205	1,656,994	48,666	--	14,185,811	Majority: yes
Proposal 4. Vote, on an Advisory Basis, on the Frequency of the Say-On-Pay vote.	18,094,953	12,793,033	25,879	--	14,185,811	Majority: yes
Proposal 6. Approval of an Amendment to the Company's Sixth Amended and Restated Certificate of Incorporation to Increase the Number of Authorized Shares of Common Stock from 100,000,000 to 200,000,000.	42,417,621	2,655,416	26,639	--	--	Majority: yes
Proposal 7. Approval of an Amendment to the Company's Sixth Amended and Restated Certificate of Incorporation Allowing Officer Exculpation as Permitted by Delaware Law.	29,642,641	1,235,007	36,217	--	14,185,811	Majority: yes

Source: Protara Therapeutics, Inc., Form 8-K, filed with the SEC on 2026-06-15 — read the filing on EDGAR.

How asset managers voted at the Protara Therapeutics, Inc. 2025-2026 meeting

Each item below shows how the 112 asset managers that disclosed a Protara Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Protara Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. Approval, on an advisory basis, of the compensation of our named executive officers, as disclosed in the proxy statement

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%

FOR: 29,208,205AGAINST: 1,656,994

Protara Therapeutics, Inc.’s own tally for this item (“Proposal 3. Approval, on an Advisory Basis, of the Compensation of the Company's Named Executive Officers.”): 29,208,205 for, 1,656,994 against, per its Form 8-K filed 2026-06-15 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 56,204,237 outstanding shares: 52.0% for, 3% against (54.9% of the company cast a for/against vote).

The 111 asset managers below cast 98% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.

FOR 98%

FOR: 98.4%AGAINST: 1.6%ABSTAIN: 0.0%

Largest asset managers voting on “Approval, on an advisory basis, of the compensation of our named executive officers, as disclosed in the proxy” at Protara Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
Janus Henderson	10,277,914	0	For
BlackRock	2,910,827	1,239	For
Vanguard	2,869,488	4	For
Velan Capital Investment Management LP	2,720,875	0	For
5AM Venture Management, LLC	1,369,782	0	For
GEODE CAPITAL MANAGEMENT, LLC	1,146,623	0	For
Blackstone Inc.	1,085,038	0	For
Fidelity	1,078,830	0	For
AIGH Capital Management LLC	886,403	0	For
State Street	867,090	774	For
Integral Health Asset Management, LLC	743,885	0	For
J. Goldman & Co LP	687,727	0	For
ADAR1 Capital Management, LLC	457,544	0	For
Point72	374,756	0	For
Northern Trust	344,152	0	For
Charles Schwab	295,776	0	For
Dimensional	257,423	0	For
Catalio Capital Management, LP	250,350	0	For
American Century	0	187,212	Against
OPPENHEIMER & CO INC	185,376	0	For
CIBC Capital Markets (Europe) S.A.	171,495	0	For
CIBC WORLD MARKET INC.	171,495	0	For
MELLON INVESTMENTS Corp	158,068	0	For
SUPERSTRING CAPITAL MANAGEMENT LP	121,457	0	For
Asset Management One Co., Ltd.	99,566	0	For

Showing the 25 largest of 111 asset managers. See all 111 in the interactive database.

2. Vote, on an advisory basis, as to whether the stockholder advisory vote to approve the compensation of our named executive officers, (i.e., Proposal 3) should occur every one, two or three years

SECTION 14A SAY-ON-PAY VOTES

Combines 2 wordings of this item as funds reported it.

100% fund support · no official result

ONE YEAR 67%1 YEAR 20%9%

The 109 asset managers below cast 100% of the shares they voted on this item FOR (771,721 for, 0 against).

FOR: 771,721 (2.6%)ABSTAIN: 178 (0.0%)ONE YEAR: 20,151,287 (67.4%)1 YEAR: 5,983,070 (20.0%)1.0: 2,720,937 (9.1%)THREE YEARS: 259,259 (0.9%)3 YEARS: 8,362 (0.0%)3.0: 9 (0.0%)2.0: 2 (0.0%)

Largest asset managers voting on “Vote, on an advisory basis, as to whether the stockholder advisory vote to approve the compensation of our nam” at Protara Therapeutics, Inc., 2025-2026
Asset manager	For	Vote
Janus Henderson	0	One Year
BlackRock	0	1 Year
Vanguard	0	One Year
Velan Capital Investment Management LP	0	1.0
5AM Venture Management, LLC	0	1 Year
GEODE CAPITAL MANAGEMENT, LLC	0	One Year
Blackstone Inc.	0	One Year
Fidelity	0	One Year
State Street	0	One Year
Integral Health Asset Management, LLC	743,885	For
J. Goldman & Co LP	0	1 Year
ADAR1 Capital Management, LLC	0	One Year
Point72	0	One Year
Northern Trust	0	1 Year
Charles Schwab	0	1 Year
Dimensional	0	Three Years
American Century	0	One Year
OPPENHEIMER & CO INC	0	1 Year
CIBC Capital Markets (Europe) S.A.	0	One Year
CIBC WORLD MARKET INC.	0	One Year
MELLON INVESTMENTS Corp	0	One Year
Asset Management One Co., Ltd.	0	One Year
Alyeska Investment Group, L.P.	0	One Year
Renaissance	0	One Year
QUANTITATIVE MASTER SERIES LLC	0	1 Year

Showing the 25 largest of 109 asset managers. See all 109 in the interactive database.

3. Approval of an amendment to the Protara Therapeutics, Inc. 2024 Equity Incentive Plan

COMPENSATION

74% fund support · no official result

FOR 74%AGAINST 26%

The 39 asset managers below cast 74% of the shares they voted on this item FOR (5,124,551 for, 1,813,123 against).

FOR: 5,124,551 (73.9%)AGAINST: 1,813,123 (26.1%)

Largest asset managers voting on “Approval of an amendment to the Protara Therapeutics, Inc. 2024 Equity Incentive Plan” at Protara Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
Vanguard	2,504,413	3,637	For
BlackRock	1,457,933	0	For
Fidelity	0	1,022,335	Against
Integral Health Asset Management, LLC	743,885	0	For
Dimensional	0	199,658	Against
Charles Schwab	147,888	0	For
Northern Trust	0	143,797	Against
American Century	0	93,606	Against
QUANTITATIVE MASTER SERIES LLC	83,507	0	For
Equitable	80,732	2,510	For
TIAA	0	63,860	Against
BRIDGEWAY FUNDS INC	0	63,000	Against
ALPS ETF Trust	0	44,029	Against
Nationwide	16,784	18,617	Against
Lincoln Financial	0	25,700	Against
AIG/SunAmerica	0	24,900	Against
Global X	24,135	0	For
Bridge Builder Trust	22,692	0	For
Pacific Life	19,494	0	For
Brighthouse	0	16,701	Against
Goldman Sachs	14,671	0	For
State Street	0	13,814	Against
John Hancock	0	13,484	Against
AQR	0	10,978	Against
Voya	0	8,624	Against

Showing the 25 largest of 39 asset managers. See all 39 in the interactive database.

4. Approval of an amendment to our sixth amended and restated certificate of incorporation allowing officer exculpation as permitted by Delaware law

CORPORATE GOVERNANCEMajority of the votes cast: yes

96% Majority: yes · of votes cast

FOR 96%

FOR: 29,642,641AGAINST: 1,235,007

Protara Therapeutics, Inc.’s own tally for this item (“Proposal 7. Approval of an Amendment to the Company's Sixth Amended and Restated Certificate of Incorporation Allowing Officer Exculpation as Permitted by Delaware Law.”): 29,642,641 for, 1,235,007 against, per its Form 8-K filed 2026-06-15 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 56,204,237 outstanding shares: 52.7% for, 2% against (54.9% of the company cast a for/against vote).

The 38 asset managers below cast 99.4% of the shares they voted on this item FOR (6,160,235 for, 33,555 against).

FOR 99.4%

FOR: 6,160,235 (99.5%)AGAINST: 33,555 (0.5%)

Largest asset managers voting on “Approval of an amendment to our sixth amended and restated certificate of incorporation allowing officer excul” at Protara Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
Vanguard	2,506,314	1,737	For
BlackRock	1,457,933	0	For
Fidelity	1,022,335	0	For
Dimensional	199,658	0	For
Charles Schwab	147,888	0	For
Northern Trust	143,797	0	For
American Century	93,606	0	For
QUANTITATIVE MASTER SERIES LLC	83,507	0	For
Equitable	83,242	0	For
TIAA	63,860	0	For
BRIDGEWAY FUNDS INC	63,000	0	For
ALPS ETF Trust	44,029	0	For
Nationwide	32,794	2,607	For
Lincoln Financial	25,700	0	For
AIG/SunAmerica	24,900	0	For
Global X	0	24,135	Against
Bridge Builder Trust	22,692	0	For
Pacific Life	19,494	0	For
Brighthouse	16,701	0	For
Goldman Sachs	14,671	0	For
State Street	13,814	0	For
John Hancock	13,484	0	For
AQR	10,978	0	For
Voya	8,624	0	For
Jackson National	8,362	0	For

Showing the 25 largest of 38 asset managers. See all 38 in the interactive database.

5. Approval of an amendment to our sixth amended and restated certificate of incorporation to increase the number of authorized shares of common stock from 100,000,000 to 200,000,000

CAPITAL STRUCTUREMajority of the votes cast: yes

94% Majority: yes · of votes cast

FOR 94%

FOR: 42,417,621AGAINST: 2,655,416

Protara Therapeutics, Inc.’s own tally for this item (“Proposal 6. Approval of an Amendment to the Company's Sixth Amended and Restated Certificate of Incorporation to Increase the Number of Authorized Shares of Common Stock from 100,000,000 to 200,000,000.”): 42,417,621 for, 2,655,416 against, per its Form 8-K filed 2026-06-15 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 56,204,237 outstanding shares: 75% for, 5% against (80% of the company cast a for/against vote).

The 38 asset managers below cast 99.9% of the shares they voted on this item FOR (6,190,168 for, 3,621 against).

FOR 99.9%

FOR: 6,190,168 (99.9%)AGAINST: 3,621 (0.1%)

Largest asset managers voting on “Approval of an amendment to our sixth amended and restated certificate of incorporation to increase the number” at Protara Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
Vanguard	2,504,429	3,621	For
BlackRock	1,457,933	0	For
Fidelity	1,022,335	0	For
Dimensional	199,658	0	For
Charles Schwab	147,888	0	For
Northern Trust	143,797	0	For
American Century	93,606	0	For
QUANTITATIVE MASTER SERIES LLC	83,507	0	For
Equitable	83,242	0	For
TIAA	63,860	0	For
BRIDGEWAY FUNDS INC	63,000	0	For
ALPS ETF Trust	44,029	0	For
Nationwide	35,401	0	For
Lincoln Financial	25,700	0	For
AIG/SunAmerica	24,900	0	For
Global X	24,135	0	For
Bridge Builder Trust	22,692	0	For
Pacific Life	19,494	0	For
Brighthouse	16,701	0	For
Goldman Sachs	14,671	0	For
State Street	13,814	0	For
John Hancock	13,484	0	For
AQR	10,978	0	For
Voya	8,624	0	For
Jackson National	8,362	0	For

Showing the 25 largest of 38 asset managers. See all 38 in the interactive database.

6. Election of three Class III directors to the Board of Directors of Protara Therapeutics, Inc., each to hold office until the annual meeting of stockholders in 2029: Barry Flannelly, Pharm.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

82% Majority: yes · of votes cast

FOR 82%WITHHELD 18%

FOR: 25,409,066WITHHELD: 5,504,799

Protara Therapeutics, Inc.’s own tally for this item (“Elect Director: Barry Flannelly, Pharm.D.”): 25,409,066 for, 5,504,799 withheld, per its Form 8-K filed 2026-06-15 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 56,204,237 outstanding shares: 45.2% for, 10% withheld (55% of the company cast a for/withheld vote).

The 38 asset managers below cast 100% of the shares they voted on this item FOR (5,481,204 for, 0 against).

FOR 88%12%

FOR: 5,481,204 (88.5%)ABSTAIN: 712,585 (11.5%)

Largest asset managers voting on “Election of three Class III directors to the Board of Directors of Protara Therapeutics, Inc., each to hold of” at Protara Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	2,504,419	3,631	For
BlackRock	1,457,933	0	For
Fidelity	1,022,335	0	For
Dimensional	0	199,658	Abstain
Charles Schwab	147,888	0	For
Northern Trust	0	143,797	Abstain
American Century	0	93,606	Abstain
QUANTITATIVE MASTER SERIES LLC	83,507	0	For
Equitable	80,732	2,510	For
TIAA	63,860	0	For
BRIDGEWAY FUNDS INC	0	63,000	Abstain
ALPS ETF Trust	0	44,029	Abstain
Nationwide	16,784	18,617	Abstain
Lincoln Financial	0	25,700	Abstain
AIG/SunAmerica	0	24,900	Abstain
Global X	24,135	0	For
Bridge Builder Trust	22,692	0	For
Pacific Life	19,494	0	For
Brighthouse	0	16,701	Abstain
Goldman Sachs	14,671	0	For
State Street	0	13,814	Abstain
John Hancock	0	13,484	Abstain
AQR	0	10,978	Abstain
Voya	8,624	0	For
Jackson National	0	8,362	Abstain

Showing the 25 largest of 38 asset managers. See all 38 in the interactive database.

7. Election of three Class III directors to the Board of Directors of Protara Therapeutics, Inc., each to hold office until the annual meeting of stockholders in 2029: Cynthia Smith

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

72% Majority: yes · of votes cast

FOR 72%WITHHELD 28%

FOR: 22,371,125WITHHELD: 8,542,740

Protara Therapeutics, Inc.’s own tally for this item (“Elect Director: Cynthia Smith”): 22,371,125 for, 8,542,740 withheld, per its Form 8-K filed 2026-06-15 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 56,204,237 outstanding shares: 40% for, 15% withheld (55% of the company cast a for/withheld vote).

The 38 asset managers below cast 100% of the shares they voted on this item FOR (3,788,754 for, 0 against).

FOR 61%ABSTAIN 39%

FOR: 3,788,754 (61.2%)ABSTAIN: 2,405,035 (38.8%)

Largest asset managers voting on “Election of three Class III directors to the Board of Directors of Protara Therapeutics, Inc., each to hold of” at Protara Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	2,504,411	3,639	For
BlackRock	0	1,457,933	Abstain
Fidelity	1,022,335	0	For
Dimensional	0	199,658	Abstain
Charles Schwab	147,888	0	For
Northern Trust	0	143,797	Abstain
American Century	0	93,606	Abstain
QUANTITATIVE MASTER SERIES LLC	0	83,507	Abstain
Equitable	0	83,242	Abstain
TIAA	63,860	0	For
BRIDGEWAY FUNDS INC	0	63,000	Abstain
ALPS ETF Trust	0	44,029	Abstain
Nationwide	0	35,401	Abstain
Lincoln Financial	0	25,700	Abstain
AIG/SunAmerica	0	24,900	Abstain
Global X	24,135	0	For
Bridge Builder Trust	0	22,692	Abstain
Pacific Life	0	19,494	Abstain
Brighthouse	0	16,701	Abstain
Goldman Sachs	14,671	0	For
State Street	0	13,814	Abstain
John Hancock	0	13,484	Abstain
AQR	0	10,978	Abstain
Voya	0	8,624	Abstain
Jackson National	0	8,362	Abstain

Showing the 25 largest of 38 asset managers. See all 38 in the interactive database.

8. Election of three Class III directors to the Board of Directors of Protara Therapeutics, Inc., each to hold office until the annual meeting of stockholders in 2029: Jesse Shefferman

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

86% Majority: yes · of votes cast

FOR 86%14%

FOR: 26,672,259WITHHELD: 4,241,606

Protara Therapeutics, Inc.’s own tally for this item (“Elect Director: Jesse Shefferman”): 26,672,259 for, 4,241,606 withheld, per its Form 8-K filed 2026-06-15 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 56,204,237 outstanding shares: 47.5% for, 8% withheld (55% of the company cast a for/withheld vote).

The 38 asset managers below cast 100% of the shares they voted on this item FOR (5,669,019 for, 0 against).

FOR 92%8%

FOR: 5,669,019 (91.5%)ABSTAIN: 524,770 (8.5%)

Largest asset managers voting on “Election of three Class III directors to the Board of Directors of Protara Therapeutics, Inc., each to hold of” at Protara Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	2,504,421	3,629	For
BlackRock	1,457,933	0	For
Fidelity	1,022,335	0	For
Dimensional	0	199,658	Abstain
Charles Schwab	147,888	0	For
Northern Trust	143,797	0	For
American Century	0	93,606	Abstain
QUANTITATIVE MASTER SERIES LLC	83,507	0	For
Equitable	83,242	0	For
TIAA	63,860	0	For
BRIDGEWAY FUNDS INC	0	63,000	Abstain
ALPS ETF Trust	0	44,029	Abstain
Nationwide	16,784	18,617	Abstain
Lincoln Financial	25,700	0	For
AIG/SunAmerica	0	24,900	Abstain
Global X	24,135	0	For
Bridge Builder Trust	22,692	0	For
Pacific Life	19,494	0	For
Brighthouse	0	16,701	Abstain
Goldman Sachs	14,671	0	For
State Street	13,814	0	For
John Hancock	0	13,484	Abstain
AQR	0	10,978	Abstain
Voya	8,624	0	For
Jackson National	0	8,362	Abstain

Showing the 25 largest of 38 asset managers. See all 38 in the interactive database.

9. Ratification of the selection by the audit committee of our board of directors of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2026

AUDIT-RELATEDMajority of the votes cast: yes

99.8% Majority: yes · of votes cast

FOR 99.8%

FOR: 45,012,036AGAINST: 74,615

Protara Therapeutics, Inc.’s own tally for this item (“Proposal 2. Ratification of the Selection of Independent Registered Public Accounting Firm.”): 45,012,036 for, 74,615 against, per its Form 8-K filed 2026-06-15 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 56,204,237 outstanding shares: 80% for, 0.2% against (80% of the company cast a for/against vote).

The 38 asset managers below cast 100% of the shares they voted on this item FOR (6,193,790 for, 0 against).

FOR 100%

FOR: 6,193,790 (100.0%)

Largest asset managers voting on “Ratification of the selection by the audit committee of our board of directors of Ernst & Young LLP as our ind” at Protara Therapeutics, Inc., 2025-2026
Asset manager	For	Vote
Vanguard	2,508,051	For
BlackRock	1,457,933	For
Fidelity	1,022,335	For
Dimensional	199,658	For
Charles Schwab	147,888	For
Northern Trust	143,797	For
American Century	93,606	For
QUANTITATIVE MASTER SERIES LLC	83,507	For
Equitable	83,242	For
TIAA	63,860	For
BRIDGEWAY FUNDS INC	63,000	For
ALPS ETF Trust	44,029	For
Nationwide	35,401	For
Lincoln Financial	25,700	For
AIG/SunAmerica	24,900	For
Global X	24,135	For
Bridge Builder Trust	22,692	For
Pacific Life	19,494	For
Brighthouse	16,701	For
Goldman Sachs	14,671	For
State Street	13,814	For
John Hancock	13,484	For
AQR	10,978	For
Voya	8,624	For
Jackson National	8,362	For

Showing the 25 largest of 38 asset managers. See all 38 in the interactive database.

Largest Protara Therapeutics, Inc. shareholders voting in 2025-2026

Ranked by the number of Protara Therapeutics, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 56,204,237 shares outstanding at the time of that meeting.

Top Protara Therapeutics, Inc. shareholders by shares voted, 2025-2026
#	Asset manager	% of shares outstanding
1	Janus Henderson	18.29%
2	BlackRock	5.18%
3	Vanguard	5.11%
4	Velan Capital Investment Management LP	4.84%
5	5AM Venture Management, LLC	2.44%
6	GEODE CAPITAL MANAGEMENT, LLC	2.04%
7	Blackstone Inc.	1.93%
8	Fidelity	1.92%
9	AIGH Capital Management LLC	1.58%
10	State Street	1.54%

Reported Protara Therapeutics, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Protara Therapeutics, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
JANUS HENDERSON GROUP Ltd.	8.36%	13G
BlackRock	6.04%	13F
Millennium Management	5.04%	13F
Vanguard Group	4.26%	13F
Jesse Shefferman	3.81%	DEF14A
Citadel Advisors	2.19%	13F
Geode Capital	2.09%	13F
Point72	2.05%	13F
State Street	1.79%	13F
Dimensional Fund Advisors	0.95%	13F

Percentages above are of 56,204,237 shares outstanding, as reported by Protara Therapeutics, Inc. on its Form 10-Q dated 2026-05-08 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Protara Therapeutics, Inc.’s 10-Q dated 2026-05-08. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.

At Protara Therapeutics, Inc.'s shareholder meeting held 2026-06-12, in the 2025-2026 proxy season, 112 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,110 separate fund positions. Their filings are grouped here into 9 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — Approval, on an advisory basis, of the compensation of our named executive officers, as… — FOR was 95% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Protara Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-15.

Protara Therapeutics, Inc. proxy season coverage: 2025-2026 (this page).